The Global Myelofibrosis Therapeutics Market (2018-2022): Set to Exceed 7% CAGR - ResearchAndMarkets.com
The "Global Myelofibrosis Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.
Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/JAK2 inhibitor used for treating the patients with myelofibrosis.
HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis.
Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease.
Increasing number of companies entering the myelofibrosis segment
Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.
Limited market size as myelofibrosis is a rare disorder
The number of available therapies, including the orphan drugs, for this disorder is very limited. The treatment options employed by physicians are mostly off-label drugs that are meant for the treatment of some other condition or blood transfusion or stem cell transplantation.
- Bristol-Myers Squibb
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT
- Comparison by type of treatment
- Drug therapy - Market size and forecast 2017-2022
- Blood transfusion - Market size and forecast 2017-2022
- HSCT - Market size and forecast 2017-2022
- Androgen Therapy - Market size and forecast 2017-2022
- Market opportunity by type of treatment
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- HSCT is the only curative option for myelofibrosis
- High off-label prescription including hydroxyurea, Immunomodulators, and steroids
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb
For more information about this report visit https://www.researchandmarkets.com/research/cpjg4d/the_global?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005657/en/